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What's New in Crohn's Disease Treatment 
Francis J. Owens, MD* 
Progress in the management of Crohn's disease is limited by 
our inability to compare different patients. Two methods of 
evaluating the severity of disease have recently been pub-
lished. Of these, the National Cooperative Crohn's Disease 
Study (NCCDS) method has been utilized in a study reported 
on at several national meetings but still in progress. 
Antibiotics in intensive prolonged dosage, e.g. ampicillin, 
500 mg qid for several months, have recently been reported 
to benefit greater than 90% of patients not responding to 
conventional therapy. Metronidazole and dapsone continue 
to be mentioned in letters to journals. Sulfasalazine has been 
found useful in active small intestinal as well as colonic 
Crohn's in the NCCDS, although not in preventing relapses. 
Corticosteroids have been shown to be of value in active 
Crohn's but not in asymptomatic patients. 
A new preparation is parenteral coherin, a peptide from 
bovine posterior pituitary. In a study of 19 critically i l l 
Crohn's patients, it reduced or eliminated steroids in 14 
cases. 
Immunosuppressants continue to have indefinite support. 
The NCCDS showed no definite benefit, yet adherents 
persist. Immunostimulants, in the light of recent T-cell 
deficiency, warrant consideration, and preliminary reports 
are interesting. 
Elemental diets and total parenteral nutrition have been 
reported to induce remissions, but recurrences have fol-
lowed. Surgical indications have been significantly corre-
lated statistically with features associated with different 
clinical groups, small intestinal, ileocolic, and colic. II-
eorectostomy has been found useful in a small group of 
patients, while hemorrhoid treatment has been shown to 
have more complications in Crohn's than in CUC. 
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Patient Evaluation 
IMPROVEMENT in the management of Crohn's disease is 
hampered by variations in descriptions of severity. Re-
producible standards in evaluating patients are needed in 
order to compare different types of therapy. Two methods 
have been published recently by Talstad and Gjone' and by 
Best et al.^ The former assigns each of the standard symp-
toms of disease activity a rating of one to four points, with 
thetotal indicating severity of disease. This rating correlated 
well with the erythrocyte sedimentation rate. The latter 
method, designated the Crohn's Disease Activity Index 
(CDAI), developed using computer analysis of signs and 
symptoms for discriminative and predictive value, and has 
been adopted for the National CooperativeCrohn's Disease 
Study (NCCDS). The CDAI was correlated statistically with 
general assessment of patient status inthe usual termsof very 
well, fair, poor, and very poor. Some of the data already 
reported from that study are included in this presentation. 
Antibiotic Therapy 
Antibiotics in Crohn's disease include broad spectrum 
antibiotics, dapsone, and metronidazole. Moss et aP re-
ported on the use of broad spectrum antibiotics in Crohn's 
disease at the 1977 American Gastroenterological Associa-
tion meeting. Forty-four patients who had failed to respond 
to conventional treatment were studied, with a mean follow-
up of two years. 
Treatment included ampicillin, 500 mg four times daily, or 
tetracycline, 250 mg three times daily. Control of abdominal 
pain and diarrhea occurred in 90%, and the average patient 
was able to sustain a reduction in the dosage of prednisone 
from 30 to 10 mg every other day. The full study is not yet 
published, but ft seems to correspond to many other reports 
of antibacterial treatment, including sterilization of the 
intestine. 
Although dapsone has been reported to be of benefit, the 
communications about metronidazole are more numerous. 
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In Ursing and Kamme'soriginal report on metronidazole for 
Crohn's disease," four of f ive patients were improved 
in two to four weeks. Because 40 mg/kg produced intolera-
ble side effects, the dosage was reduced to 20 mg/kg. Even 
then, peripheral neuropathic symptoms occurred. In animal 
experiments using 25 times the maximum human dose, 
cerebellar and brain stem lesions occurred.'^ Metronidazole 
was thought to exert its effect in Crohn's disease by suppress-
ing anaerobic bacteria. However, Arabi and associates,*^ 
reporting to the British Society of Gastroenterology in 
September 1977, found that ft had no effect on colonic 
microflora. 
Sulfasalazine (salicylazo-sulfapyridine) is not included 
among the antibacterial agents because of its multiple 
possible actions. It has effects on bacteria, inflammation, 
and prostaglandin synthesis, to mention a few, but its mode 
of action in Crohn's disease has not been defined. Previously 
it was thought to be more valuable in colonic involvement, 
but Anthonisen et aP have shown its benefit in small 
intestinal disease as well. 
In active symptomatic Crohn's disease the National Cooper-
ative Crohn's Disease Study (NCCDS) found a statistically 
significant benefit of sulfasalazine as compared to placebo if 
the patient had not been treated with steroids. However, 
sulfasalazine has not prevented recurrences in asymptoma-
tic Crohn's patients. In a report in Cut,"* 43 multicenter post-
resection and/or asymptomatic patients double-blindly 
treated with sulfasalazine or placebo were subjected to 
statistical analysis. The conclusion was that there was no 
benefit from sulfasalazine. In a comparison of drugs and 
placeboes the NCCDS^° also found no statistically signifi-
cant benefit from sulfasalazine in preventing relapse in one 
or two years. 
Corticosteroids are acknowledged by most clinicians to be 
of value in controlling Crohn's disease in relapse. The 
NCCDS" compared corticosteriod treatment (prednisone) 
with placeboes in active symptomatic Crohn's disease. 
There was a definite benefit statistically from prednisone 
both in patients who had been treated with steroids and in 
those who had not. 
The prevention of recurrences in the asymptomatic Crohn's 
patient is another story. One study included both corticoster-
oids and sulfasalazine. Bergman and Krause" reported on 
97 mult icenter post-resection patients who were ran-
domized into a group treated for 33 weeks wfth corticoster-
oids and sulfasalazine and an untreated group. After one, 
two, and three years there was no difference in recurrence 
between the two groups. The NCCDS^° also compared 
prednisone and placebo in asymptomatic patients, but 
reported no benefit from prednisone in one or two years in 
preventing relapse. 
Another hormonal preparation that has recently been re-
ported by Hiattand Goodman" to be ofvalue is coherin, a 
peptide substance from the bovine posterior pituitary gland. 
Its action was found to regularize electromotor activity inthe 
small intestine ofthe fasting dog; hence the possible use in 
diarrheal diseases. In a study of 19 patients who were 
resistant to other treatment, coherin was beneficial to 18. 
Four of five who were receiving no other treatment at the 
time improved with coherin, while 14 who had been treated 
previously with both steroids and coherin improved also. In 
nine of the 14, steroid treatment was discontinued, and in 
five, steroids were decreased to 15 mgor less. This report, of 
course, wil l need further investigation. 
Immune Therapy 
Immunosuppressants continue to present an enigma. While 
some investigators have reported on steroid-sparing effects, 
others have reported no effects from azathioprine. Brooke et 
a l " reviewed 112 patients treated with azathioprine or 
prednisone and concluded thatthey provided no long-term 
benefit although they were helpful for remissions. Compar-
ing azathioprine with placebo in symptomatic Crohn's, the 
NCCDS'found no benefit from it statistically. Furthermore, ft 
had no value in preventingrecurrences^°atoneortwoyears 
in asymptomatic patients. 
The use of immunostimulants in Crohn's disease should 
correct the immunodeficiencies of T-cells that have been 
suggested. Bertrand et aP" reported that levamisole cor-
rected some immunodeficiencies and has seemed to put 
patients into remission. But more recently, Segal et a l " 
reported that arthrftis occurred when levamisole was used 
but cleared when it was stopped. Hematologic, gastroin-
testinal, and central nervous system side effects have also 
been ascribed to levamisole used for other conditions. 
Finally, in a report to the British Society of Gastroenterology 
(September 1977), Wesdorp et al found no beneficial effect 
from levamisole on clinical, biochemical, and immunologi-
cal disturbances in Crohn's. 
Nutritional Therapy 
Nutritional therapy has included elemental diets and total 
parenteral nutrition. Axelsson and Jarnum^'' reported remis-
sions in seven of 11 patients on an elemental diet. Other 
reports have alluded to lack of patient acceptance and 
occurrence of relapse. Reilly et a l " reported some benefit 
from hyperalimentation in most patients with Crohn's dis-
ease, although not in ulcerative colitis. Fazio etaP" reported 
that many patients benefited from hyperalimentation, and 
some avoided planned surgical procedures. However, later 
follow-up of these patients disclosed that many subse-
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quently relapsed, and most required the operation originally 
planned. 
Surgery 
Farmer et a l " studied surgical indications in 500 patients 
operated upon for Crohn's disease. Statistical correlation of 
intestinal obstruction, internal fistula and abscess, perianal 
disease, and poor response to medical therapy wfth small 
intestinal, ileocolic, and colic patterns was identified. 
Ileorectal anastomosis for Crohn's disease ofthe colon was 
studied in 66 patients by Lefton et aP" who found the results 
excellent in 26 (roughly 40%). Twelve were satisfactory, 21 
unsatisfactory, and 7 were incomplete in that the diversion-
ary ileostomy and IRA were done without subsequent 
closure ofthe ileostomy, usually because of recurrent rectal 
disease. More recently, Flint et aP' have reported better 
results in fewer patients but with a shorter average follow-up 
time. 
Finally, hemorrhoid treatment has been reviewed by Jeffery 
et aP^ in Crohn's and ulcerative colitis patients. A high 
complication rate was found primarily in Crohn's disease. 
Summary 
Progress in the management of Crohn's disease is limited by 
our inability to compare the disease status of different 
patients. Two methods of evaluating severity of disease have 
recently been introduced. 
Elemental diets and total parenteral nutrition induce remis-
sions, but recurrences may follow. Ileorectostomy has been 
useful and lasting in a small group of patients, but hemor-
rhoid treatment has more complications in Crohn's disease 
than in CUC. Classification of several broad groups of 
patients accordingto anatomical involvement has permitted 
statistical correlation with different surgical indications. 
Broad spectrum antibiotics, metronidazole, immunosup-
pressants, immunostimulants, (and coherin, a peptide from 
bovine posterior pituitary)are possible treatment modal ities 
that need further trials. However, sulfasalazine and cortico-
steroid treatment have proven valuable in active Crohn's 
disease. Thus, improvement in the treatment of Crohn's 
disease would be greatly facilitated by the demonstration of 
the manner of action ofthese agents. Thereby, further search 
foragents, whether of antibacterial, hormonal, immunosup-
pressant, or immunostimulant activity, could be intensified. 
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